Due to the COVID – 19 Pandemic the 17th Annual ENETs (physical) Conference was cancelled and in its place a Virtual Conference was held from 11-13 March.
Despite the conference being virtual it was still an interactive event with live Q&A sessions held). All sessions have been recorded which for attendees in Australia has been very fortunate as the live times were in the middle of the night for us!
As previous conferences, abstracts were submitted and this year saw a record in terms of the number of abstracts received (361 in total) and unparalleled in terms of the quality of submitted basic science abstracts.
NeuroEndocrine Cancer Australia were pleased to be involved in 6 scientific abstracts, our highest to date.
Either as funding, or directly undertaking the research we are very proud of what has been able to be achieved.
Despite ENETs not taking place in a physical sense we are grateful to the organisers for allowing the meeting to take place virtually and for abstracts and posters to still be able to be promoted.
We will be doing a full summary of the meeting in our next e-news.
- PlaNET Registry Abstract
- Peter MacCallum (Centre of Excellence, Melbourne Australia) Data experience
- Nutritional Status and Considerations for Patients Diagnosed with a Gastroenteropancreatic Neuroendocrine Tumour
- Nutrition in NETs study funded by NeuroEndocrine Cancer Australia
- Financial Toxicity Report
- The financial implications on Australian’s living with neuroendocrine tumours
- GP Education Research
- Leading planned online modules for Australian GP’s through 2020 and beyond
- INCA SCAN Survey
- Assessing preliminary access results
- Control NETs Clinical Trial
- finding the optimal treatment to improve disease control in patients with advanced Neuroendocrine tumours (NETs)
The conference commenced with the Post Graduate Course which is in its 10th year of running.
In 2019 there were more than 800 participants. The numbers of attendees’ has been rapidly increasing each year. This year the content included Clinical Management from a practical perspective, controversial treatment of Neuroendocrine neoplasms(NENs), surveillance, PRRT in Non GEP NETs, Liver transplantation, generic tailored treatments for Phaeochromocytoma and Paraganglioma, and Immunotherapy.
There was an excellent overview of Carcinoid Heart Disease which discussed “When is the optimal time to intervene”.
Over the next two days presentations included were PRRT (dosing and scheduling, assessing response to PRRT and re-challenging with PRRT), systemic treatments, Clinical Trials – Internationally, Mixed Neuroendocrine Non Neuroendocrine Neoplasms (MiNEN formerly known as MANEC – Mixed Adenocarcinoma Neuroendocrine Carcinoma) and Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH). MiNEN and DIPNECH presentations provided information about the pathophysiology and clinical aspects of the disease.
Currently, we are working through viewing all the recorded sessions and will provide more information in the next eNews on topics of interest and new research.